How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,503 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Erythroderma (Generalized Exfoliative Dermatitis) (Diagnosis)

Erythroderma (Generalized Exfoliative Dermatitis) (Diagnosis) Erythroderma (Generalized Exfoliative Dermatitis): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi1vdmVydmlldw== processing > Erythroderma (Generalized Exfoliative Dermatitis) Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Overview Background Exfoliative dermatitis (ED) is a definitive term that refers to a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Exfoliative dermatitis is characterized by erythema and scaling involving

2014 eMedicine.com

42. A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus The safety and scientific validity of this study

2012 Clinical Trials

43. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction Full Text available with Trip Pro

[57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second-generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After (...) Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI).Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality.Among 2189 patients with MI (mean+/-SD age, 68+/-14 years; 1237 men

2009 EvidenceUpdates

44. Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes mellitus Men or women age ≥ 18 years old Stable dose combination of metformin and sulfonylurea HbA1c ≥7.7% and ≤11.0% Exclusion Criteria: Type 1 diabetes mellitus (...) Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2011 Clinical Trials

45. Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Recruitment Status : Completed First Posted : March 18, 2011 Results First Posted : August 16, 2012 Last Update Posted : August 16, 2012 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID). Condition or disease Intervention/treatment Phase Type 2 Diabetes (...) Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2011 Clinical Trials

46. Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01318083 Recruitment Status : Completed First Posted : March (...) 18, 2011 Results First Posted : July 6, 2011 Last Update Posted : February 3, 2012 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study was evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an Sulfonylurea taken QD or twice daily (BID) in type 2 diabetic patients with uncontrolled blood glucose. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug

2011 Clinical Trials

47. Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

: Completed First Posted : April 18, 2011 Last Update Posted : April 18, 2011 Sponsor: Sanofi Information provided by: Sanofi Study Details Study Description Go to Brief Summary: Study Primary Objectives: To compare glycemic control, as measured by hemoglobin A1c (A1C), between insulin glargine and 75% insulin lispro protamine suspension/25% insulin lispro as add-on therapies in subjects who failed oral combination therapy with sulfonylurea and metformin. Study Secondary Objectives : To compare (...) Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2011 Clinical Trials

48. Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Status : Completed First Posted : April 25, 2011 Results First Posted : October 8, 2012 Last Update Posted : June 5, 2017 Sponsor: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Merck Sharp & Dohme Corp. Study Details Study Description Go to Brief Summary: This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose (...) Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2011 Clinical Trials

49. General Principles of Poisoning

General Principles of Poisoning General Principles of Poisoning - Injuries; Poisoning - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge (...) , which are unpredictable and not dose-related, and from intolerance, which is a toxic reaction to a usually nontoxic dose of a substance. Poisoning is commonly due to ingestion but can result from injection, inhalation, or exposure of body surfaces (eg, skin, eye, mucous membranes). Many commonly ingested nonfood substances are generally nontoxic (see Table: ); however, almost any substance can be toxic if ingested in excessive amounts. Table Substances Usually Not Dangerous When Ingested* Adhesives

2013 Merck Manual (19th Edition)

50. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes

-of-rights). Page 3 of 131 1 Recommendations Recommendations 1.1 Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: a dipeptidyl peptidase 4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. 1.2 Ertugliflozin in a dual-therapy regimen in combination with metformin (...) is recommended as an option for treating type 2 diabetes, only if: a sulfonylurea is contraindicated or not tolerated or the person is at significant risk of hypoglycaemia or its consequences. 1.3 If patients and their clinicians consider ertugliflozin to be 1 of a range of suitable treatments including canagliflozin, dapagliflozin and empagliflozin, the least expensive should be chosen. 1.4 These recommendations are not intended to affect treatment with ertugliflozin that was started in the NHS before

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

51. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

4 Table 4: Research question of the benefit assessment of dapagliflozin in type 2 diabetes mellitus 5 Table 5: Study pool of the company – RCT, direct comparison: dapagliflozin+metformin vs. sulfonylurea + metformin 6 Table 6: Characteristics of the DapaZu study included by the company – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 7 Table 7: Characteristics of the intervention – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 8 (...) ”) submitted a first dossier of the drug to be evaluated on 15 December 2012 for the early benefit assessment. The company now requested a new benefit assessment for a subindication – i.e. an add-on combination therapy with metformin – because of new scientific findings. The assessment was based on a dossier compiled by the pharmaceutical company. The dossier was sent to IQWiG on 21 December 2017. Research question The aim of this report was to assess the added benefit of dapagliflozin for the treatment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

52. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

2 diabetes mellitus 1 Table 3: Dapagliflozin/metformin – probability and extent of added benefit 4 Table 4: Research question of the benefit assessment of dapagliflozin/metformin in type 2 diabetes mellitus 5 Table 5: Study pool of the company – RCT, direct comparison: dapagliflozin/metformin vs. sulfonylurea + metformin 6 Table 6: Characteristics of the DapaZu study included by the company – RCT, direct comparison: dapagliflozin + metformin vs. glimepiride + metformin 8 Table 7: Characteristics (...) and Efficiency in Health Care (IQWiG) - 1 - 2 Benefit assessment 2.1 Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned IQWiG to assess the benefit of the drug combination dapagliflozin/metformin. The company submitted a first dossier on the drug combination on 15 February 2014 to be evaluated for the early benefit assessment. The company now requested a new benefit assessment for a subindication – i.e

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

53. Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)

investigated in this report is referred to as research question B to match its designation in the first and second assessment of sitagliptin. Table 2 2 : Research questions of the benefit assessment of sitagliptin plus metformin Research question Indication ACT a B Sitagliptin plus metformin ? Sulfonylurea (glibenclamide or glimepiride) b plus metformin or ? Empagliflozin plus metformin or ? Liraglutide c plus metformin a: Presentation of the respective ACT specified by the G-BA. In cases where the ACT (...) for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Günther Egidi, practice for general medicine, Bremen IQWiG thanks the medical and scientific advisor for his/her contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment: ? Virginia Seiffart ? Ulrich Grouven

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

54. Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

for semaglutide Research question Indication a ACT b A Monotherapy if diet and exercise alone fail to adequately control blood glucose in patients who are ineligible to use metformin due to intolerance or contraindications ? Sulfonylurea (glibenclamide or glimepiride) B Combination with another antihyperglycaemic (except for insulin) if this drug, combined with diet and exercise, fails to adequately control blood glucose ? Metformin + sulfonylurea (glibenclamide or glimepiride) or ? Metformin + empagliflozin (...) of the drug semaglutide in comparison with the ACT is assessed as presented in Table 3: 3 Depending on the number of studies analysed, the certainty of their results, and the direction and statistical significance of treatment effects, conclusions on the probability of (added) benefit or harm are graded into 4 categories: (1) “proof”, (2) “indication”, (3) “hint”, or (4) none of the first 3 categories applies (i.e., no data available or conclusions 1 to 3 cannot be drawn from the available data

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

55. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

? Sulfonylurea (glibenclamide or glimepiride) 2 Combination with one other blood-glucose lowering drug (except insulin, here metformin), when this, together with diet and exercise, does not provide adequate glycaemic control ? Metformin + sulfonylurea (glibenclamide or glimepiride) or ? metformin + empagliflozin or ? metformin + liraglutide c 3 Combination with one other blood-glucose lowering drug (except insulin and metformin), when this, together with diet and exercise, does not provide adequate glycaemic (...) control ? Metformin + sulfonylurea (glibenclamide or glimepiride) or ? metformin + empagliflozin or ? metformin + liraglutide c or ? human insulin if metformin is not tolerated or contraindicated according to the SPC 4 Combination with at least 2 other blood-glucose lowering drugs (except insulin), when these, together with diet and exercise, do not provide adequate glycaemic control ? Human insulin + metformin or ? human insulin + empagliflozin c or ? human insulin + liraglutide c or ? human insulin

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

56. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

of dapagliflozin/metformin Research question Subindication a ACT b 1 Combination with one other blood-glucose lowering drug (except insulin, here metformin), when this, together with diet and exercise, does not provide adequate glycaemic control ? Metformin + sulfonylurea (glibenclamide or glimepiride) or ? metformin + empagliflozin or ? metformin + liraglutide c 2 Combination with at least 2 other blood-glucose lowering drugs (including metformin, except insulin), when these, together with diet and exercise (...) of the scientific data analysed, IQWiG draws conclusions on the (added) benefit or harm of an intervention for each patient-relevant outcome. Depending on the number of studies analysed, the certainty of their results, and the direction and statistical significance of treatment effects, conclusions on the probability of (added) benefit or harm are graded into 4 categories: (1) “proof”, (2) “indication”, (3) “hint”, or (4) none of the first 3 categories applies (i.e., no data available or conclusions 1 to 3

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

57. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

Sulfonylureas 38 8.5.3 Thiazolidinediones 38 8.5.4 Dipeptidyl peptidase-4 inhibitors 38 8.5.5 Glucagon-like peptide-1 receptor agonists 38 8.5.6 Sodium-glucose co-transporter 2 inhibitors 38 9 Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death 40 9.1 Atrial fibrillation 40 9.1.1 Diabetes and risk of stroke in atrial fibrillation 40 9.2 Ventricular arrhythmias and sudden cardiac death 40 9.2.1 Ventricular premature beats and paroxysmal ventricular tachycardia 40 9.2.2 (...) -centred care 46 12.1 General aspects 46 13 ‘What to do’ and ‘what not to do’ messages from the Guidelines 48 14 Appendix 51 15 References 52 Recommendations Recommendations for the diagnosis of disorders of glucose metabolism 12 Recommendations for the use of laboratory, electrocardiogram, and imaging testing for cardiovascular risk assessment in asymptomatic patients with diabetes 16 Recommendations for lifestyle modifications for patients with diabetes mellitus and pre-diabetes 18 Recommendations

2019 European Society of Cardiology

58. Management of Poisoning

with poison centre follow-up. A patient suspected of a signi? cant overdose is at risk of serious toxicity and serotonin syndrome (pg 136). Grade D, Level 3 Antipsychotics B Clinical manifestations of atypical antipsychotic toxicity generally include varying degrees of central nervous system depression (drowsiness), agitation, anticholinergic effects, pupillary changes, seizures, hypotension or hypertension, and cardiac conduction abnormalities (prolongation of the QTc and QRS intervals). Clozapine has (...) ; olanzapine 10 mg; quetiapine 100 mg; risperidone 25 1 mg; or ziprasidone 80mg) (pg 141). Grade C, Level 3 C Clinical manifestations of typical antipsychotics poisoning generally include neuroleptic malignant syndrome, rigidity, dystonia, fever and widened QRS interval (pg 141). Grade C, Level 2+ D The primary treatment of cardiotoxicity is plasma alkalinisation with sodium bicarbonate and hyperventilation (pg 141). Grade D, Level 4 GPP Patients with altered mental state or persistent tachycardia despite

2020 Ministry of Health, Singapore

59. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

and durable ventricular assist devices, transplantation capabilities, and specialists in advanced heart failure, cardiothoracic surgery, cardiac pathology, immunology, and infectious disease. Education of frontline providers who are most likely to encounter FM first is essential to increase timely access to appropriately resourced facilities, to prevent multiorgan system failure, and to tailor disease-specific therapy as early as possible in the disease process. Fulminant: adjective ful··mi··nant | coming (...) . It may present as sudden death and is considered an important diagnostic consideration by the American College of Cardiology and American Heart Association (AHA) for sudden death in competitive athletes. Cardiogenic or mixed cardiogenic and distributive shock may develop rapidly, often soon after first medical contact. In one of the most comprehensive clinicopathological descriptions of myocarditis, investigators from Johns Hopkins were among the first to report the paradoxical complete recovery

2020 American Heart Association

60. Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease

for All-Cause Mortality 40 Figure 6. Meta-Analysis of SGLT-2 Inhibitors vs. Placebo for Mortality from Cardiovascular Causes 41 Appendices 42 Appendix A. Summarized Estimates of Treatment Effects 42 Appendix A Table 1. Estimates * of Treatment Effect of Sulfonylureas and Thiazolidinediones from Palmer, 2016 4 42 Appendix A Table 2. Estimates of Treatment Effect of DPP-4s, GLP-1s, and SGLT-2s from Zheng, 2018 5 44 Appendix B. Eligibility Criteria for Randomized Clinical Trials 45 Appendix C. Literature (...) Events Reporting System for Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors, by Medication 53 Appendix H. Detailed Quality Assessment Results for Randomized Controlled Trials 54 1 Context/Background Standard of care in clinical practice is to use metformin as the first-line medication for glucose-lowering in type 2 diabetes. 1-3 A number of different medications are available as next line therapy in persons whose diabetes is not adequately controlled on metformin, or for whom metformin

2019 Kaiser Permanente National Guideline Program

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>